Pacific Biosciences of California PACB AFS Securities
AFS Securities at other companies
Other financials
Where this comes from
Reported directly by Pacific Biosciences of California in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtMaturitiesRollingYearTwoThroughFiveFairValue.
The official record: Pacific Biosciences of California’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Pacific Biosciences of California's afs securities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Pacific Biosciences of California's AFS securities?
- Pacific Biosciences of California (PACB) reported AFS securities of $83.15M in Q1 2026.
- How has Pacific Biosciences of California's AFS securities changed year-over-year?
- Pacific Biosciences of California's AFS securities increased by 14.7% year-over-year, from $72.48M to $83.15M.
- What is the long-term trend for Pacific Biosciences of California's AFS securities?
- Over 2 years (2020 to 2022), Pacific Biosciences of California's AFS securities has grown at a -53.2% compound annual growth rate (CAGR), from $318.81M to $69.93M.
- What does AFS securities mean?
- Debt securities classified as available-for-sale, measured at fair value with unrealized gains/losses in OCI rather than the income statement.